IP Library › Granted Patent US 10,307,455

Granted Patent B2

US 10,307,455 · App. 15/456,392 · Granted Jun 4, 2019

Activin type 2 receptor antibodies

Inventors: Ravindra Kumar (Cambridge, MA); Jonathan Belk (Lebanon, NH); Asya Grinberg (Cambridge, MA); Dianne Sako (Cambridge, MA); Roselyne Castonguay (Cambridge, MA)

Assignees: Acceleron Pharma Inc.; Adimab, LLC

A61K38/02 A61K38/16 C07K14/001 C07K14/47 A61K38/00 C07K5/00

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 10,307,455
App. No.: 15/456,392
Granted: Jun 4, 2019
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.

Claims (270)

1. An ActRII-binding antibody comprising a set of CDRs in which:

(a) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO:166;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO:167;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO:168;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO:173;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO:174; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO:175;

and wherein the antibody binds ActRIIB;

(b) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 3 or 17;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 4 or 18;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 5;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 10;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 11; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 12;

and wherein the antibody binds ActRIIB;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 65 or 79;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 66 or 80;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 71;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 72; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO:73;

and wherein the antibody binds ActRIIB;

(d) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 3 or 58;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 4 or 59;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 46;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 51;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 52; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 53;

and wherein the antibody binds ActRIIB;

(e) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 145;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 146;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 147;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 152;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 153; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 154;

and wherein the antibody binds ActRIIB;

(f) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 85 or 99;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 86 or 100;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 87 or 101;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA;

(g) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 126;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 127;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 128;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 133;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 134; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 135;

and wherein the antibody binds ActRIIA;

h) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 3 or 17;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 24 or 30;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 5:

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 10;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 11; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 12;

and wherein the antibody binds ActRIIB;

(i) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 3 or 17;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 36;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 5;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 10;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 11; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 12;

and wherein the antibody binds ActRIIB;

(j) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 23 or 29;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 4 or 18;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 5;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 10;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 11; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 12;

and wherein the antibody binds ActRIIB;

(k) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 23 or 29;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 24 or 30;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 5;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 10;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 11; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 12;

and wherein the antibody binds ActRIIB;

(l) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 23 or 29;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 36;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 5;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 10;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 11; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 12;

and wherein the antibody binds ActRIIB:

(m) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 35 or 41;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 4 or 18;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 5;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 10;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 11; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 12;

and wherein the antibody binds ActRIIB:

(n) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 35 or 41;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 24 or 30;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 5;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 10;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 11; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 12;

and wherein the antibody binds ActRIIB;

(o) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 35 or 41;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 36;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 5;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 10;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 11; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 12;

and wherein the antibody binds ActRIIB;

(p) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 85 or 99;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 86 or 100;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 108 or 115

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA;

(g) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 85 or 99;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 86 or 100;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 121;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA;

(r) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 85 or 99;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 107 or 114;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 87 or 101;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA;

(s) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 85 or 99;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 107 or 114;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 108 or 115;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA;

(t) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 85 or 99;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 107 or 114;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 121;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA;

(u) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 85 or 99;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 120;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 87 or 101;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA;

(v) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 85 or 99;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 120;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 108 or 115;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA;

(w) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 85 or 99;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 120;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 121;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA;

(x) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 106 or 113;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 86 or 100;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 87 or 101;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA;

(y) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 106 or 113;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 86 or 100;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 108 or 115;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA;

(z) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 106 or 113;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 86 or 100;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 121;

(iv) VL-CDR has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO:93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA;

(aa) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 106 or 113;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 107 or 114;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 87 or 101;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA;

(bb) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 106 or 113;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 107 or 114;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 108 or 115;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA;

(cc) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 106 or 113;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 107 or 114;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 121;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA;

(dd) (i) VH-CDRI has the amino acid sequence of SEQ ID NO: 106 or 113;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 120;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 87 or 101;

(iv) VL-CDRI has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA;

(ee) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 106 or 113;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 120;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 108 or 115;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA;

(ff) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO: 106 or 113;

(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO: 120;

(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO: 121;

(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO: 92;

(v) VL-CDR2 has the amino acid sequence of SEQ ID NO: 93; and

(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO: 94;

and wherein the antibody binds ActRIIB and ActRIIA.

2. The ActRII-binding antibody of claim 1 , which comprises a VH and a VL pair selected from:

(a) a VH sequence of SEQ ID NO:165 and a VL sequence of SEQ ID NO:172;

(b) a VH sequence of SEQ ID NO:2 and a VL sequence of SEQ ID NO:9;

(d) a VH sequence of SEQ ID NO:22 and a VL sequence of SEQ ID NO:9;

(e) a VH sequence of SEQ ID NO:28 and a VL sequence of SEQ ID NO:9;

(f) a VH sequence of SEQ ID NO:34 and a VL sequence of SEQ ID NO:9;

(g) a VH sequence of SEQ ID NO:40 and a VL sequence of SEQ ID NO:9;

(h) a VH sequence of SEQ ID NO:45 and a VL sequence of SEQ ID NO:50;

(i) a VH sequence of SEQ ID NO:57 and a VL sequence of SEQ ID NO:50;

(j) a VH sequence of SEQ ID NO:63 and a VL sequence of SEQ ID NO:70;

(k) a VH sequence of SEQ ID NO:77 and a VL sequence of SEQ ID NO:70;

(l) a VH sequence of SEQ ID NO:144 and a VL sequence of SEQ ID NO:151;

(m) a VH sequence of SEQ ID NO:84 and a VL sequence of SEQ ID NO:91;

(n) a VH sequence of SEQ ID NO:98 and a VL sequence of SEQ ID NO:91;

(o) a VH sequence of SEQ ID NO:105 and a VL sequence of SEQ ID NO:91;

(p) a VH sequence of SEQ ID NO:112 and a VL sequence of SEQ ID NO:91;

(q) a VH sequence of SEQ ID NO:119 and a sequence of SEQ ID NO:91; and

(r) a VH sequence of SEQ ID NO:125 and a sequence of SEQ ID NO:132.

3. The ActRII-binding antibody of claim 1 , wherein the antibody has at least one characteristic selected from:

(a) competing with activin A, activin B, BMP7, BMP9, BMP10, GDF8 (myostatin), GDF11, or Nodal, for binding to ActRIIB or ActRIIA;

(b) decreasing the phosphorylation of one or more Smads in cells expressing ActRIIB and/or ActRIIA in the presence of an ActRIIB or ActRIIA ligand;

(c) decreasing the phosphorylation of ALK4 or ALK7 in cells expressing ActRIIB or ActRIIA and ALK4 or ALK7 in the presence of an ActRIIB or ActRIIA ligand; and

(d) binding to ActRIIB or ActRIIA with a KD of ≤1 nM and ≥1 pM, as determined by BIACORE® analysis.

4. The ActRII-binding antibody of claim 1 , wherein the antibody is a monoclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, a chimeric antibody, a bi-specific antibody, a multi-specific antibody, or an ActRII-binding antibody fragment.

5. The ActRII-binding antibody of claim 4 , wherein the ActRII-binding antibody fragment is selected from a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, a Fv fragment, a diabody, or a single chain antibody molecule.

6. The ActRII-binding antibody of claim 4 , wherein the antibody further comprises a heavy chain immunoglobulin constant domain selected from:

(a) a human IgA constant domain;

(b) a human IgD constant domain;

(d) a human IgG1 constant domain;

(e) a human IgG2 constant domain;

(f) a human IgG3 constant domain;

(g) a human IgG4 constant domain; and

(h) a human IgM constant domain.

7. The ActRII-binding antibody of claim 4 , wherein the antibody further comprises a light chain immunoglobulin constant domain selected from:

(a) a human Ig kappa constant domain; and

(b) a human Ig lambda constant domain.

8. The ActRII-binding antibody of claim 4 , wherein the antibody further comprises a human IgG1 heavy chain constant domain and a human lambda light chain constant domain.

9. An isolated nucleic acid molecule or a set of nucleic acid molecules that encodes the ActRII-binding antibody of claim 1 .

10. A vector comprising the nucleic acid molecule or the set of nucleic acid molecules according to claim 9 .

11. A host cell comprising the nucleic acid molecule or the set of nucleic acid molecules according to claim 9 .

12. A method of making an ActRII-binding antibody, said method comprising culturing the host cell according to claim 11 under suitable conditions for producing the ActRII-binding antibody.

13. An ActRII-binding antibody produced using the method of claim 12 .

14. A pharmaceutical composition comprising the ActRII-binding antibody according to claim 1 and a pharmaceutically acceptable carrier.

Assignments (5)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2020

From: ADIMAB, LLC

To: ACCELERON PHARMA INC.

Reel/Frame 053805/0243 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2020

From: KUMAR, RAVINDRA; GRINBERG, ASYA; SAKO, DIANNE; CASTONGUAY, ROSELYNE

To: ACCELERON PHARMA INC.

Reel/Frame 053152/0859 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2020